What are the 2026 ESC Guidelines for the Management of Heart Failure?
The 2026 ESC Guidelines for the Management of Heart Failure are evidence-based clinical practice guidelines developed by the European Society of Cardiology, with contributions from its Heart Failure Association and endorsement by the European Association for Cardio-Thoracic Surgery. It supports healthcare professionals in heart failure prevention, diagnosis, treatment, complication management, and long-term patient care.
Introduction
Heart failure is a complex clinical syndrome that requires accurate diagnosis, individualized treatment, careful monitoring, and coordinated long-term care. From identifying patients at risk to managing decompensated disease and evaluating advanced treatment options, clinicians need reliable guidance that reflects current evidence and evolving clinical practice.
The 2026 ESC Guidelines for the Management of Heart Failure provide a comprehensive reference for healthcare professionals seeking structured recommendations across the heart failure care pathway.
Developed by the European Society of Cardiology (ESC), with a special contribution from the Heart Failure Association (HFA) of the ESC, and endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), this guideline updates the previous 2021 ESC heart failure guideline.
A particularly important aspect of this edition is its updated approach to heart failure classification, prevention, pharmacological treatment, and interventional management. It also addresses decompensated heart failure, advanced disease, cardiovascular and non-cardiovascular comorbidities, cardiac amyloidosis, and multidisciplinary follow-up.
For cardiologists, internal medicine physicians, residents, medical students, nurses, pharmacists, and clinical researchers, the guideline offers an organized framework for understanding contemporary heart failure management. Its recommendations and evidence tables help readers connect clinical decisions with the strength of the supporting evidence.
This review examines the guideline's scope, organization, educational value, and practical applications, helping readers determine how it may support their clinical learning and professional development.
Book Overview
2026 ESC Guidelines for the Management of Heart Failure
Clinical practice guideline · Cardiology
A comprehensive European guideline addressing the prevention, diagnosis, treatment, and long-term management of heart failure.
Full title: 2026 ESC Guidelines for the Management of Heart Failure
Edition: 2026 guideline edition; edition number not specified
Chairpersons: Lars Køber and Marianna Adamo
Task force coordinators: Anne-Christine Ruwald and Daniela Tomasoni
Publisher: Oxford University Press, through the European Heart Journal
Publication year: 2026
Developing organization: European Society of Cardiology (ESC)
Contributing organization: Heart Failure Association (HFA) of the ESC
Endorsing organization: European Association for Cardio-Thoracic Surgery (EACTS)
Medical specialty: Cardiology, particularly heart failure medicine
Intended audience: Healthcare professionals, medical students, residents, allied health professionals, and researchers
What Makes the 2026 ESC Heart Failure Guidelines Important?
The guideline is designed to help clinicians navigate heart failure from its earliest stages through advanced disease. Rather than concentrating exclusively on medication selection, it brings together prevention, diagnostic assessment, pharmacological therapy, device-based interventions, management of acute deterioration, comorbidities, and continuing care.
Several changes distinguish the 2026 edition from the 2021 ESC guideline. These include revised heart failure classifications and the adoption of stages (A through D), a new framework for categorizing treatments, and updated recommendations supported by a revised evidence-grading system.
The document also provides recommendation tables, evidence tables, clinical algorithms, and illustrations. These resources make it useful both as a comprehensive reference and as a practical aid when reviewing a particular clinical question.
Importantly, the ESC emphasizes that guidelines support rather than replace professional judgment. Treatment decisions must account for the patient's clinical condition, preferences, applicable local regulations, and any newer guidance.
What This Book Covers
The 2026 ESC Guidelines for the Management of Heart Failure are organized into 19 numbered sections, beginning with the guideline's preamble and introduction and extending through evidence tables, appendices, and references. The main clinical chapters cover the full spectrum of heart failure care.
1. Definition, Epidemiology, and Classification of Heart Failure
The opening clinical section establishes the terminology used throughout the guideline. It examines the definition of heart failure, its epidemiology, natural history, prognosis, and different classification systems.
A major update in the 2026 edition is the revised classification according to left ventricular ejection fraction (LVEF). The guideline expands the category of heart failure with reduced ejection fraction (HFrEF) to include LVEF values up to 50%, removes heart failure with mildly reduced ejection fraction (HFmrEF) as a separate category, and defines heart failure with preserved ejection fraction (HFpEF) as LVEF of 50% or higher.
It also adopts stages A–D, ranging from patients at risk of heart failure to those with advanced disease. These changes are important for clinicians who need to understand the terminology used in current recommendations and interpret treatment guidance within the appropriate clinical framework.
2. Prevention of Heart Failure
Prevention receives dedicated attention, reflecting the importance of identifying risk before symptomatic disease develops.
Topics include cardiometabolic risk factors, lifestyle-related risks, diet and physical activity, smoking, alcohol and substance use, arrhythmias, myocardial infarction, chronic kidney disease, cancer survivors, genetic predisposition, pulmonary disorders, endocrine conditions, and congenital heart disease.
The guideline also discusses patients with asymptomatic left ventricular dysfunction and valvular heart disease. This section helps readers understand how heart failure prevention extends beyond treating established symptoms to recognizing and addressing risk factors earlier in the disease course.
For medical students and residents, it provides a useful framework for linking cardiovascular risk assessment with preventive clinical practice.
3. Diagnosis of Chronic Heart Failure
Accurate diagnosis is essential to appropriate management. The guideline outlines the diagnostic process for suspected chronic heart failure and discusses the role of natriuretic peptides, other laboratory investigations, cardiac imaging, and assessment of the underlying cause.
The diagnostic sections include:
- Natriuretic peptide testing and interpretation.
- Laboratory investigations in suspected heart failure.
- Classification according to LVEF.
- Assessment of heart failure with reduced and preserved ejection fraction.
- Investigation of the underlying aetiology.
- Multimodality cardiac imaging.
- Evaluation for coronary artery disease.
- Assessment of arrhythmia-associated heart failure and abnormal cardiac conduction.
The document also addresses specialized investigations for potentially reversible or treatable causes of heart failure. Its diagnostic algorithms and recommendation tables can help clinicians organize investigations rather than approaching every patient with an identical testing strategy.
4. Management of Chronic Heart Failure
Chronic heart failure treatment is one of the guideline's major clinical components. It separates foundational medical therapy from additional medical treatments and guideline-directed interventional therapies.
The pharmacological sections cover several important drug classes and therapeutic approaches, including:
- Sodium–glucose co-transporter 2 inhibitors (SGLT2 inhibitors).
- Mineralocorticoid receptor antagonists (MRAs).
- Loop diuretics.
- Angiotensin-converting enzyme inhibitors (ACE inhibitors).
- Angiotensin receptor–neprilysin inhibitors (ARNIs).
- Angiotensin receptor blockers (ARBs).
- Beta-blockers.
- Ivabradine, vericiguat, hydralazine, and isosorbide dinitrate.
- Cardiac glycosides and cardiac myosin activation.
- Potassium binders.
The guideline distinguishes treatments used across heart failure populations from those specifically addressed for HFrEF, HFpEF, or patients whose ejection fraction has improved.
Another important subject is the optimization of foundational medical therapy. The 2026 recommendations address treatment uptitration, maintaining adherence, and continuing therapy in patients who become asymptomatic or experience improvement in LVEF.
For clinicians, this structure provides a useful reference when reviewing treatment priorities, evaluating changes in a patient's condition, and planning ongoing medication optimization. Actual prescribing must still reflect contraindications, laboratory findings, hemodynamic status, and individual patient needs.
5. Devices and Interventional Therapies
Heart failure management sometimes requires more than medication. The guideline includes a substantial discussion of implantable devices and interventional treatment strategies.
These topics include:
- Implantable cardioverter-defibrillators (ICDs).
- Cardiac resynchronization therapy (CRT).
- Conduction system pacing.
- Device programming and follow-up.
- Other cardiac implantable electronic devices.
- Additional implantable devices and interventions.
The guideline addresses patient selection, indications, and timing for device-based treatment. It also discusses the management of right ventricular pacing-induced heart failure and heart failure associated with abnormal cardiac conduction.
These sections are especially relevant to cardiology trainees and practicing cardiologists who need to understand how device therapy fits within an integrated management plan.
6. Decompensated Heart Failure
The guideline uses the term decompensated heart failure in place of the previous terminology of acute heart failure.
This section covers clinical presentation, diagnosis, general management, and treatment. It includes left-sided and right-sided decompensation, acute pulmonary oedema, and cardiogenic shock.
The management framework is divided into three phases:
- Initial management.
- Stabilization.
- Pre-discharge care and early post-discharge management.
Specific treatment topics include oxygen therapy, ventilatory support, diuretic-based decongestion, SGLT2 inhibitors, ultrafiltration, vasodilators, inotropes and inodilators, vasopressors, temporary mechanical circulatory support, and thromboembolism prophylaxis.
The phased structure is educationally useful because it highlights that successful management does not end when a patient first stabilizes. Discharge preparation and early follow-up are also important parts of the care pathway.
7. Advanced Heart Failure
Advanced heart failure requires careful assessment, timely referral, and consideration of specialized interventions. The guideline discusses the definition, prognosis, evaluation, and referral of patients with advanced disease or those at high risk of progression.
Its coverage includes:
- Pharmacological treatment and kidney replacement therapy.
- Temporary and durable mechanical circulatory support.
- Left ventricular assist devices (LVADs).
- Heart transplantation.
- Symptom control and end-of-life care.
The guideline also includes criteria relevant to LVAD implantation and heart transplantation. This makes the section useful for clinicians who need to recognize when conventional management may no longer be sufficient, and specialist assessment may be appropriate.
8. Cardiovascular and Non-Cardiovascular Comorbidities
Heart failure frequently coexists with other conditions that complicate treatment and affect patient outcomes. The guideline addresses cardiovascular comorbidities such as atrial fibrillation, ventricular arrhythmias, bradyarrhythmias, chronic coronary syndromes, valvular heart disease, hypertension, and stroke.
It also examines non-cardiovascular comorbidities, including:
- Obesity and diabetes.
- Chronic kidney disease.
- Iron deficiency and anaemia.
- Cancer.
- Lung disease and sleep-disordered breathing.
- Anxiety, depression, and cognitive impairment.
- Frailty and other non-cardiovascular conditions.
This broad coverage is valuable for clinicians managing patients whose symptoms, treatment tolerance, and care requirements are influenced by multiple interacting conditions.
9. Multidisciplinary Care and Long-Term Follow-Up
The guideline recognizes that heart failure care extends beyond the prescription of medication or completion of a procedure.
Dedicated sections discuss multidisciplinary team management, patient education, self-care, lifestyle advice, treatment implementation, adherence, exercise training, cardiac rehabilitation, telemonitoring, and long-term follow-up.
Advance care planning and palliative care are also included, particularly in the context of advanced disease.
For nurses, pharmacists, rehabilitation professionals, and medical educators, these chapters help connect medical treatment with the broader responsibilities of patient education, monitoring, coordination, and continuity of care.
10. Specific Conditions
The final clinical chapters address selected conditions requiring particular consideration in heart failure management:
- Pregnancy and heart failure.
- Cardiomyopathies, including hypertrophic cardiomyopathy.
- Cardiac amyloidosis, including immunoglobulin light-chain and transthyretin cardiac amyloidosis.
- Myocarditis.
- Adult congenital heart disease.
These sections broaden the guideline's relevance beyond routine presentations of chronic heart failure and help readers recognize when condition-specific evaluation and management may be required.
The guideline concludes with key messages, gaps in evidence, evidence tables, data availability, author information, an appendix, and references.
Key Features
The educational strengths of the 2026 ESC Guidelines for the Management of Heart Failure include the following:
- Updated heart failure classification: Introduces revised LVEF categories and stages A–D.
- Comprehensive clinical coverage: Addresses prevention, diagnosis, chronic management, decompensation, and advanced disease.
- Structured recommendations: Uses formal recommendation classes to communicate the strength of clinical recommendations.
- Explicit evidence grading: Includes a revised evidence framework for therapy, prevention, diagnostic tests, and prediction models.
- Clinical algorithms: Provides diagnostic and management figures that organize complex decision pathways.
- Evidence tables: Summarizes key information supporting specific recommendation tables.
- Pharmacological guidance: Separates foundational, additional, and interventional therapies.
- Device-based treatment: Covers ICDs, CRT, conduction system pacing, and mechanical circulatory support.
- Comorbidity management: Addresses cardiovascular and non-cardiovascular conditions that influence heart failure care.
- Multidisciplinary perspective: Includes patient education, rehabilitation, telemonitoring, follow-up, and palliative care.
- Dedicated sections on special populations and conditions: Includes pregnancy, cardiomyopathies, amyloidosis, myocarditis, and adult congenital heart disease.
Who Should Read This Book?
Medical Students
Medical students can use the guideline to consolidate their understanding of heart failure classification, diagnostic investigations, treatment categories, and common complications. Its chapter structure is also helpful when organizing revision around major clinical themes.
It is best used alongside foundational cardiology textbooks, particularly when the student needs to understand the reasoning behind a clinical recommendation rather than memorize an isolated fact.
Residents and Interns
Residents in internal medicine, cardiology, emergency medicine, and related specialties may find the guideline especially useful for clinical rotations and case discussions.
The diagnostic algorithms and sections on decompensated heart failure provide an organized way to review patient assessment, while the chronic management chapters support learning about medication optimization and follow-up.
Cardiologists and Other Specialists
Practicing cardiologists can use the document as a reference when reviewing treatment recommendations, device indications, advanced heart failure assessment, and management of associated conditions.
Internists and other specialists involved in cardiovascular care may benefit from its broad coverage of comorbidities and multidisciplinary management.
Why the 2026 ESC Heart Failure Guidelines Are Useful
Clinical Relevance
One of the guideline's principal strengths is its coverage of the entire heart failure pathway. Readers can move from prevention and early recognition to diagnostic evaluation, chronic treatment, acute deterioration, and advanced care without relying on a single narrow clinical perspective.
This makes the document useful for understanding how decisions made at one stage of care relate to subsequent management and follow-up.
Evidence-Based Recommendations
The guideline describes a formal process for evaluating the medical literature, weighing the balance of benefits and risks, grading recommendations, and assessing the evidence supporting them.
It includes evidence tables linked to recommendation tables and a revised framework for grading the evidence. For clinicians and researchers, this provides a structured starting point for understanding not only what is recommended, but also the stated strength of the recommendation and its evidentiary basis.
The presence of evidence grading should not be interpreted as a guarantee that every recommendation is supported by equally strong evidence. The guideline explicitly distinguishes among levels of evidentiary certainty.
Practical Applications
The guideline's diagnostic algorithms, treatment recommendations, and management figures can help readers organize clinical questions.
For example, a clinician reviewing a patient with suspected chronic heart failure can consult the diagnostic sections, while a clinician managing a hospitalized patient can refer to the phased approach to decompensated heart failure. Separate sections address device selection, advanced disease, and specific comorbidities.
These resources support clinical reasoning, but they do not replace a comprehensive patient assessment or individualized decision-making.
Value for Board and Postgraduate Examinations
The document covers many of the major themes encountered in postgraduate cardiology and internal medicine education, including LVEF classification, pharmacological management, diagnostic testing, cardiac devices, and advanced heart failure.
Its recommendation tables and clinical figures can be used to create revision notes and case-based questions. Nevertheless, learners should check the examination syllabus and use appropriate textbooks or question banks to cover material outside the guideline's scope.
Learning Efficiency
The guideline's structured chapters, tables, figures, and evidence summaries allow readers to approach the material at different levels of detail.
A student can begin with the definitions and classification sections, a resident can focus on diagnosis and treatment, and a specialist can consult a particular recommendation or evidence table. The document is sufficiently broad to support systematic study while allowing targeted reference when a specific clinical issue arises.
Table of Contents Overview
The guideline contains 19 numbered sections. The following table summarizes its principal organization.
|
Section |
Main subject |
|
1 |
Preamble |
|
2 |
Introduction and new developments |
|
3 |
Definition, epidemiology, and classifications |
|
4 |
Prevention of heart failure |
|
5 |
Diagnosis of chronic heart failure |
|
6 |
Management of chronic heart failure |
|
7 |
Decompensated heart failure |
|
8 |
Advanced heart failure |
|
9 |
Cardiovascular comorbidities |
|
10 |
Non-cardiovascular comorbidities |
|
11 |
Multidisciplinary management, long-term follow-up, and patient care |
|
12 |
Specific conditions, including pregnancy, cardiomyopathies,
amyloidosis, myocarditis, and adult congenital heart disease |
|
13 |
Key messages |
|
14 |
Gaps in evidence |
|
15 |
Evidence tables |
|
16 |
Data availability |
|
17 |
Author information |
|
18 |
Appendix |
|
19 |
References |
Strengths of the Book
Broad Coverage of Heart Failure Care
The guideline goes beyond drug therapy to cover prevention, diagnosis, invasive and non-invasive interventions, rehabilitation, and long-term care. This comprehensive approach is valuable for clinicians who manage patients at different stages of disease.
Clear Organization of Recommendations
The distinction between foundational medical therapy, additional medical therapy, and interventional therapy provides a useful framework for understanding treatment categories. Formal recommendation classes also help readers distinguish recommendations that are strongly supported from those that require more cautious interpretation.
Attention to Early Disease and Prevention
The inclusion of stages A and B, risk factors, and asymptomatic left ventricular dysfunction expands the discussion beyond patients who already have overt clinical heart failure. This is useful for clinicians interested in early identification and prevention of disease progression.
Integration of Advanced Treatment
Coverage of mechanical circulatory support, transplantation, cardiogenic shock, and advanced heart failure makes the guideline relevant to specialist practice as well as general cardiology education.
Recognition of Comorbidities
The dedicated chapters on kidney disease, diabetes, obesity, iron deficiency, anaemia, arrhythmias, valvular disease, and other comorbidities acknowledge the complexity of real-world heart failure management.
Transparency About Evidence
The guideline includes an explicit discussion of gaps in evidence, alongside evidence tables and a description of how recommendations are developed and graded. This supports critical reading and helps learners recognize that clinical recommendations evolve as evidence changes.
Limitations
A balanced assessment should distinguish limitations of the document's format and scope from shortcomings in its clinical content.
1. It is a guideline, not a comprehensive textbook. The document is designed to communicate recommendations and evidence rather than provide an introductory explanation of every cardiovascular concept. Beginners may need a standard cardiology textbook to understand the underlying physiology and pathophysiology.
2. The clinical detail can be demanding. Its specialist terminology, recommendation tables, and evidence-grading framework may be challenging for readers without a background in cardiovascular medicine.
3. Some topics are intentionally addressed elsewhere. The guideline notes that subjects such as pregnancy, myocarditis, valvular heart disease, and chronic coronary syndromes are not discussed in full detail because separate ESC or ESC/EACTS guidelines address them. Readers seeking comprehensive coverage of those areas may need additional references.
4. Recommendations require clinical interpretation. A recommendation cannot be applied mechanically to every patient. Clinical condition, contraindications, patient preferences, local regulations, and individual circumstances remain essential to decision-making.
5. The evidence base continues to evolve. A 2026 guideline represents the evidence considered during its development. Subsequent research and updated professional recommendations may change clinical practice, so readers should verify whether a newer version is available before relying on it for current clinical decisions.
6. It is not a dedicated examination resource. The guideline provides clinically relevant material for examination preparation but does not replace a question bank, a structured revision course, or a broader medical textbook.
These limitations reflect the purpose and scope of a specialist clinical guideline rather than necessarily indicating defects in its educational quality.
Comparison With Similar Books and Guidelines
The 2026 ESC Guidelines for the Management of Heart Failure occupies a different role from a conventional cardiology textbook or a general clinical handbook.
|
Resource type |
Primary purpose |
How the 2026 ESC guideline differs |
|
General cardiology textbook |
Teaches cardiovascular physiology, pathology, diagnosis, and treatment |
The ESC guideline concentrates on recommendations for heart failure
management. |
|
Comprehensive internal medicine
textbook |
Covers a broad range of adult medical conditions |
The guideline offers greater focus on the heart failure care pathway. |
|
Clinical handbook |
Provides concise information for quick reference |
The guideline provides an extensive recommendation and evidence
framework, including dedicated evidence tables. |
|
Examination question bank |
Tests knowledge through clinical questions and explanations |
The guideline is a reference for learning and clinical recommendations,
not a question-based revision resource. |
|
American heart failure guidelines |
Provides recommendations within a different professional guideline
framework |
The ESC document reflects the European Society of Cardiology's
recommendations, terminology, and evidence-grading approach. |
The comparison is based on the general purposes of these resource types, not on a direct chapter-by-chapter assessment of named competing publications.
The most appropriate choice depends on the reader's goal. A medical student seeking foundational explanations may need a textbook first. A clinician reviewing European heart failure recommendations may find the ESC guideline more directly applicable. Researchers may use it alongside the underlying clinical trials and systematic reviews to evaluate the evidence behind particular recommendations.
For many readers, these resources are complementary rather than interchangeable.
2026 ESC Guidelines for the Management of Heart Failure
Or: Link 2
FAQs
The 2026 ESC Guidelines for the Management of Heart Failure are clinical practice recommendations developed by the European Society of Cardiology. They address heart failure prevention, diagnosis, classification, pharmacological and interventional treatment, decompensated disease, advanced heart failure, comorbidities, and long-term patient care.
The guidelines were developed by a task force of the European Society of Cardiology, with a special contribution from its Heart Failure Association. They were endorsed by the European Association for Cardio-Thoracic Surgery. Lars Køber and Marianna Adamo served as chairpersons.
The 2026 edition introduces revised heart failure classifications based on LVEF, adopts stages A–D, uses the term decompensated heart failure in place of acute heart failure, and introduces new classifications for medical and interventional therapies. It also updates recommendations and applies a revised evidence-grading system.
The guideline covers prevention, diagnosis, chronic heart failure treatment, device-based interventions, decompensated heart failure, advanced disease, cardiovascular and non-cardiovascular comorbidities, multidisciplinary care, rehabilitation, and long-term follow-up. It also discusses pregnancy, cardiomyopathies, cardiac amyloidosis, myocarditis, and adult congenital heart disease.
Yes. The guideline can support learning about heart failure classification, diagnostic pathways, treatment recommendations, and clinical decision-making. Medical students and residents may benefit most when they combine it with foundational textbooks, supervised clinical learning, and appropriate examination resources.
Yes. Pharmacists may consult the pharmacological treatment and adherence sections, while nurses and allied healthcare professionals may find the chapters on patient education, self-care, rehabilitation, telemonitoring, and multidisciplinary management particularly relevant.
The guideline uses classes of recommendation to communicate the strength of recommendations and levels of evidence to describe the supporting evidence. Its framework includes distinct approaches for therapy and prevention versus diagnostic tests and prediction models. Readers should interpret each recommendation according to its specific classification and clinical context.
No. The guideline explicitly states that recommendations support professional decision-making but do not override an individual clinician's responsibility to consider the patient's condition, preferences, applicable regulations, and other relevant updated recommendations.
Conclusion
The 2026 ESC Guidelines for the Management of Heart Failure is a comprehensive clinical reference for healthcare professionals who need an organized, evidence-based approach to heart failure prevention, diagnosis, treatment, and long-term management.
Its most valuable features include updated classification systems, structured treatment recommendations, diagnostic algorithms, evidence tables, and coverage of both routine and advanced heart failure care. The inclusion of cardiovascular comorbidities, multidisciplinary management, rehabilitation, and palliative care also reflects the complexity of caring for patients throughout the disease course.
For cardiologists, residents, internists, pharmacists, nurses, researchers, and medical educators, the guideline offers a useful reference for clinical learning and professional practice. Medical students and examination candidates can also benefit from its structured presentation, particularly when using it alongside foundational textbooks and dedicated revision materials.
The 2026 ESC heart failure guidelines are best used as a clinical practice reference rather than a substitute for comprehensive medical education or individualized clinical judgment. Readers should also consult relevant specialty guidance and verify that no newer recommendations have superseded the document.
For anyone seeking to understand contemporary European recommendations for heart failure management, this guideline provides a substantial foundation for further study, clinical discussion, and evidence-informed patient care.
Disclaimer
MedBook 4 Free does not own the copyrights to this video/book/software. We’re sharing this with our audience ONLY for educational purposes, and we strongly encourage visitors to purchase original, licensed software/books.
If the copyright owner wants us to remove this software/book, please contact us immediately. You can email [email protected] for all DMCA/removal requests.